{
    "xml": "<topic id=\"PHP2532\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/droperidol\" basename=\"droperidol\" title=\"DROPERIDOL\">\n<title>DROPERIDOL</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1152\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/butyrophenones/droperidol\">Droperidol</xref>\n</p>\n<data name=\"vtmid\">26574002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_182743901\" title=\"Antipsychotics (first-generation)\">Antipsychotics (first-generation)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP67109\" outputclass=\"drugAction\" rev=\"1.8\" parent=\"/drugs/droperidol\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Droperidol is a butyrophenone, structurally related to haloperidol, which blocks dopamine receptors in the chemoreceptor trigger zone.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66949\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/drugs/droperidol\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention and treatment of postoperative nausea and vomiting</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>0.625&#8211;1.25&#8239;mg, dose to be given 30 minutes before end of surgery, then 0.625&#8211;1.25&#8239;mg every 6&#8239;hours as required.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>625&#8239;micrograms, dose to be given 30 minutes before end of surgery, then 625&#8239;micrograms every 6&#8239;hours as required.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of nausea and vomiting caused by opioid analgesics in postoperative patient controlled analgesia (PCA)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>15&#8211;50&#8239;micrograms of droperidol for every 1&#8239;mg of morphine in PCA, reduce dose in elderly; maximum 5&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67145\" outputclass=\"contraindications\" rev=\"1.15\" parent=\"/drugs/droperidol\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Bradycardia</ph>; <ph outputclass=\"contraindication\">CNS depression</ph>; <ph outputclass=\"contraindication\">comatose states</ph>; <ph outputclass=\"contraindication\">hypokalaemia</ph>; <ph outputclass=\"contraindication\">hypomagnesaemia</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>; <ph outputclass=\"contraindication\">QT-interval prolongation</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67240\" outputclass=\"cautions\" rev=\"1.14\" parent=\"/drugs/droperidol\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Chronic obstructive pulmonary disease</ph>; <ph outputclass=\"caution\">electrolyte disturbances</ph>; <ph outputclass=\"caution\">history of alcohol abuse</ph>; <ph outputclass=\"caution\">respiratory failure</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66932\" outputclass=\"interactions\" rev=\"1.15\" parent=\"/drugs/droperidol\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (droperidol).</p>\n<p>Avoid concomitant administration of drugs that prolong QT interval.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66787\" outputclass=\"sideEffects\" rev=\"1.13\" parent=\"/drugs/droperidol\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anxiety</ph>; <ph outputclass=\"sideEffect\">cardiac arrest</ph>; <ph outputclass=\"sideEffect\">hallucinations</ph>; <ph outputclass=\"sideEffect\">inappropriate antidiuretic hormone secretion</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66897\" outputclass=\"pregnancy\" parent=\"/drugs/droperidol\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67270\" outputclass=\"breastFeeding\" parent=\"/drugs/droperidol\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Limited information available&#8212;avoid repeated administration.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67024\" outputclass=\"hepaticImpairment\" parent=\"/drugs/droperidol\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>In postoperative nausea and vomiting, max. 625&#8239;micrograms repeated every 6 hours as required.</p>\n</sectiondiv>\n<sectiondiv>\n<p>For nausea and vomiting caused by opioid analgesics in postoperative patient-controlled analgesia, reduce dose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66837\" outputclass=\"renalImpairment\" parent=\"/drugs/droperidol\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>In postoperative nausea and vomiting, max. 625&#8239;micrograms repeated every 6 hours as required.</p>\n</sectiondiv>\n<sectiondiv>\n<p>For nausea and vomiting caused by opioid analgesics in postoperative patient-controlled analgesia, reduce dose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66708\" outputclass=\"monitoringRequirements\" parent=\"/drugs/droperidol\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Continuous pulse oximetry required if risk of ventricular arrhythmia&#8212;continue for 30 minutes following administration.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2532-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/droperidol\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension, capsule</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77645\" title=\"Solution for injection\" namespace=\"/drugs/droperidol/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78221\" namespace=\"/treatment-summaries/nausea-and-labyrinth-disorders\" title=\"Nausea and labyrinth disorders\" count=\"1\" rel=\"backlink\">Nausea and labyrinth disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1152\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/butyrophenones/droperidol\" title=\"Droperidol\" count=\"1\" rel=\"link\">Droperidol</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77645\" namespace=\"/drugs/droperidol/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP2532",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/droperidol",
    "basename": "droperidol",
    "title": "DROPERIDOL",
    "interactants": [
        {
            "id": "bnf_int_1152",
            "label": "Droperidol"
        }
    ],
    "vtmid": "26574002",
    "drugClassification": [
        "Antipsychotics (first-generation)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Droperidol is a butyrophenone, structurally related to haloperidol, which blocks dopamine receptors in the chemoreceptor trigger zone.",
                "html": "<p>Droperidol is a butyrophenone, structurally related to haloperidol, which blocks dopamine receptors in the chemoreceptor trigger zone.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Prevention and treatment of postoperative nausea and vomiting",
                        "html": "Prevention and treatment of postoperative nausea and vomiting"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection"
                    ],
                    "textContent": "By intravenous injection",
                    "html": "By intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "0.625&#8211;1.25 mg, dose to be given 30 minutes before end of surgery, then 0.625&#8211;1.25 mg every 6 hours as required.",
                        "html": "<p>0.625&#8211;1.25&#8239;mg, dose to be given 30 minutes before end of surgery, then 0.625&#8211;1.25&#8239;mg every 6&#8239;hours as required.</p>"
                    },
                    {
                        "textContent": "625 micrograms, dose to be given 30 minutes before end of surgery, then 625 micrograms every 6 hours as required.",
                        "html": "<p>625&#8239;micrograms, dose to be given 30 minutes before end of surgery, then 625&#8239;micrograms every 6&#8239;hours as required.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of nausea and vomiting caused by opioid analgesics in postoperative patient controlled analgesia (PCA)",
                        "html": "Prevention of nausea and vomiting caused by opioid analgesics in postoperative patient controlled analgesia (PCA)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection"
                    ],
                    "textContent": "By intravenous injection",
                    "html": "By intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "15&#8211;50 micrograms of droperidol for every 1 mg of morphine in PCA, reduce dose in elderly; maximum 5 mg per day.",
                        "html": "<p>15&#8211;50&#8239;micrograms of droperidol for every 1&#8239;mg of morphine in PCA, reduce dose in elderly; maximum 5&#8239;mg per day.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Bradycardia",
                "html": "Bradycardia"
            },
            {
                "type": "contraindications",
                "textContent": "CNS depression",
                "html": "CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "comatose states",
                "html": "comatose states"
            },
            {
                "type": "contraindications",
                "textContent": "hypokalaemia",
                "html": "hypokalaemia"
            },
            {
                "type": "contraindications",
                "textContent": "hypomagnesaemia",
                "html": "hypomagnesaemia"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            },
            {
                "type": "contraindications",
                "textContent": "QT-interval prolongation",
                "html": "QT-interval prolongation"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Chronic obstructive pulmonary disease",
                "html": "Chronic obstructive pulmonary disease"
            },
            {
                "type": "cautions",
                "textContent": "electrolyte disturbances",
                "html": "electrolyte disturbances"
            },
            {
                "type": "cautions",
                "textContent": "history of alcohol abuse",
                "html": "history of alcohol abuse"
            },
            {
                "type": "cautions",
                "textContent": "respiratory failure",
                "html": "respiratory failure"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (droperidol).\n\nAvoid concomitant administration of drugs that prolong QT interval.",
                "html": "<p>Appendix 1 (droperidol).</p><p>Avoid concomitant administration of drugs that prolong QT interval.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Anxiety",
                        "html": "Anxiety",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "cardiac arrest",
                        "html": "cardiac arrest",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hallucinations",
                        "html": "hallucinations",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "inappropriate antidiuretic hormone secretion",
                        "html": "inappropriate antidiuretic hormone secretion",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Limited information available&#8212;avoid repeated administration.",
                "html": "<p>Limited information available&#8212;avoid repeated administration.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "In postoperative nausea and vomiting, max. 625 micrograms repeated every 6 hours as required.",
                "html": "<p>In postoperative nausea and vomiting, max. 625&#8239;micrograms repeated every 6 hours as required.</p>"
            },
            {
                "type": "doseAdjustments",
                "textContent": "For nausea and vomiting caused by opioid analgesics in postoperative patient-controlled analgesia, reduce dose.",
                "html": "<p>For nausea and vomiting caused by opioid analgesics in postoperative patient-controlled analgesia, reduce dose.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "In postoperative nausea and vomiting, max. 625 micrograms repeated every 6 hours as required.",
                "html": "<p>In postoperative nausea and vomiting, max. 625&#8239;micrograms repeated every 6 hours as required.</p>"
            },
            {
                "type": "doseAdjustments",
                "textContent": "For nausea and vomiting caused by opioid analgesics in postoperative patient-controlled analgesia, reduce dose.",
                "html": "<p>For nausea and vomiting caused by opioid analgesics in postoperative patient-controlled analgesia, reduce dose.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Continuous pulse oximetry required if risk of ventricular arrhythmia&#8212;continue for 30 minutes following administration.",
                "html": "<p>Continuous pulse oximetry required if risk of ventricular arrhythmia&#8212;continue for 30 minutes following administration.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension",
                "capsule"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77645",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78221",
                "label": "Nausea and labyrinth disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1152",
                "label": "Droperidol",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77645",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}